{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T12:32:15Z","timestamp":1768653135041,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Capital Region of Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["837004011"],"award-info":[{"award-number":["837004011"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002999","name":"Netherlands Ministry of Health Welfare and Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.annonc.2025.06.005","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T20:00:49Z","timestamp":1750276849000},"page":"1154-1165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2638-8045","authenticated-orcid":false,"given":"R.M.T.","family":"ten Ham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.W.","family":"Rohaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Egeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1378-2721","authenticated-orcid":false,"given":"R.","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Holz Borch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kessels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Jedema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Nuijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Nijenhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.V.","family":"van de Poll-Franse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.H.","family":"Geukes Foppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lindenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mansfield Noringriis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.J.","family":"Monberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Donia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.M.","family":"Svane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-7704","authenticated-orcid":false,"given":"J.B.A.G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.P.","family":"Ret\u00e8l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.annonc.2025.06.005_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2025.06.005_bib2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.annonc.2025.06.005_bib3","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1200\/JCO.20.00995","article-title":"Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma","volume":"38","author":"Robert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.06.005_bib4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.06.005_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.005_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2025.06.005_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.06.005_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.06.005_bib9","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat Med"},{"issue":"280","key":"10.1016\/j.annonc.2025.06.005_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3643","article-title":"Adoptive cellular therapy: a race to the finish line","volume":"7","author":"June","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annonc.2025.06.005_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"4770","key":"10.1016\/j.annonc.2025.06.005_bib12","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.annonc.2025.06.005_bib13","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2025.06.005_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008372","article-title":"Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial","volume":"12","author":"Ten Ham","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2025.06.005_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100588","article-title":"Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment","volume":"7","author":"Aamdal","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.annonc.2025.06.005_bib16","first-page":"561","article-title":"An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"28","author":"O\u2019Reilly","year":"2020","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.005_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/0284186X.2020.1818823","article-title":"Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls","volume":"60","author":"Boekhout","year":"2021","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.005_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2005.06.022","article-title":"The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care","volume":"42","author":"Groenvold","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2025.06.005_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.annonc.2025.06.005_bib20","series-title":"Guideline for economic evaluations in healthcare","author":"de Wit","year":"2024"},{"issue":"9","key":"10.1016\/j.annonc.2025.06.005_bib21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00019053-200826090-00002","article-title":"Guide to the Processes of Technology Appraisal","volume":"26","year":"2008","journal-title":"PharmacoEconomics"},{"issue":"3","key":"10.1016\/j.annonc.2025.06.005_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00006842-197905000-00004","article-title":"Impact of Event Scale: a measure of subjective stress","volume":"41","author":"Horowitz","year":"1979","journal-title":"Psychosom Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.005_bib23","first-page":"11","article-title":"Construct validation of the dutch version of the impact of event scale","volume":"16","author":"van der Ploeg","year":"2003","journal-title":"Psychol Assess"},{"key":"10.1016\/j.annonc.2025.06.005_bib24","series-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.annonc.2025.06.005_bib25","series-title":"Addendum to the EORTC QLQ-C30 Scoring Manual: Scoring of the EORTC QLQ-C15-PAL","author":"Groenvold","year":"2006"},{"key":"10.1016\/j.annonc.2025.06.005_bib26","series-title":"EQ-5D-3L User Guide","year":"2018"},{"issue":"4","key":"10.1016\/j.annonc.2025.06.005_bib27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40258-021-00639-3","article-title":"The Danish EQ-5D-5L value set: a hybrid model using cTTO and DCE data","volume":"19","author":"Jensen","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.annonc.2025.06.005_bib28","series-title":"Generalized Estimating Equations","author":"Hardin","year":"2003"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.005_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika"},{"key":"10.1016\/j.annonc.2025.06.005_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.annonc.2025.06.005_bib31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2190\/EA87-LDJN-LULB-VNVU","article-title":"An exploratory study of post-traumatic stress disorder symptoms among bereaved children","volume":"51","author":"McClatchey","year":"2005","journal-title":"Omega J Death Dying"},{"key":"10.1016\/j.annonc.2025.06.005_bib32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.annonc.2025.06.005_bib33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0962280213476378","article-title":"Practical and statistical issues in missing data for longitudinal patient-reported outcomes","volume":"23","author":"Bell","year":"2014","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.annonc.2025.06.005_bib34","unstructured":"Zeileis A, Grothendieck G, Ryan JA, Ulrich JM, Andrews F. S3 Infrastructure for Regular and Irregular Time Series (Z\u2019s Ordered Observations). 2023. Available at https:\/\/zoo.r-forge.r-project.org\/. Accessed July 28, 2025."},{"issue":"9","key":"10.1016\/j.annonc.2025.06.005_bib35","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s11136-023-03427-9","article-title":"Health-state utilities in long-term advanced melanoma survivors comparable with the general population","volume":"32","author":"Egeler","year":"2023","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.annonc.2025.06.005_bib36","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/pon.5674","article-title":"Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy","volume":"30","author":"Barata","year":"2021","journal-title":"Psychooncology"},{"issue":"12","key":"10.1016\/j.annonc.2025.06.005_bib37","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S1470-2045(19)30641-2","article-title":"Quality of life and CAR-T cell therapy in children, adolescents, and young adults with haematological malignancies","volume":"20","author":"Efficace","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2025.06.005_bib38","first-page":"121","article-title":"Regulation (EC) No 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and Regulation (EC) No 726\/2004 (Text with EEA relevance)","volume":"324","year":"2007","journal-title":"OJ L"},{"issue":"17","key":"10.1016\/j.annonc.2025.06.005_bib39","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.3390\/cancers15174334","article-title":"The Dutch CAR-T tumorboard experience: population-based real-world data on patients with relapsed or refractory large B-cell lymphoma referred for CD19-directed CAR T-cell therapy in the Netherlands","volume":"15","author":"Spanjaart","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.annonc.2025.06.005_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11764-023-01452-8","article-title":"\u201cOne more chance to survive\u201d: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care","volume":"19","author":"Egeler","year":"2025","journal-title":"J Cancer Surviv"},{"issue":"14","key":"10.1016\/j.annonc.2025.06.005_bib41","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials","volume":"367","author":"Little","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2025.06.005_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2025.06.005_bib43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2017.05.031","article-title":"Health-related quality of life results from the phase III CheckMate 067 study","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.06.005_bib44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jclinepi.2021.07.013","article-title":"Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials","volume":"139","author":"Olivier","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.annonc.2025.06.005_bib45","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s10198-024-01670-6","article-title":"The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands","volume":"25","author":"Pilz","year":"2024","journal-title":"Eur J Health Econ"},{"issue":"5","key":"10.1016\/j.annonc.2025.06.005_bib46","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s11136-016-1443-y","article-title":"Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L","volume":"26","author":"Lorgelly","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/j.annonc.2025.06.005_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","article-title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","volume":"86","author":"Petrella","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.06.005_bib48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7525-10-66","article-title":"Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment","volume":"10","author":"Revicki","year":"2012","journal-title":"Health Qual Life Outcomes"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425008063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425008063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:14:41Z","timestamp":1762319681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425008063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0923753425008063"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.06.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}